Non-Squamous Non-Small Cell Lung Cancer
Conditions
Brief summary
This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (\<60, 60-69, 70-79, \>80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months from the start of first-line therapy.
Interventions
None listed
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, \>/= 18 years of age * Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly non-squamous adenocarcinoma non-small cell lung cancer
Exclusion criteria
* Contraindications to Avastin treatment according to the Summary of Product Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years) | approximately 4.5 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years) | approximately 4.5 years |
| Clinical/demographic patient characteristics at initiation of treatment | approximately 4.5 years |
| Avastin treatment schedule in routine clinical practice (dosage/duration) | approximately 4 years |
| Concomitant anti-neoplastic therapy (dosage/duration) | approximately 4.5 years |
| Safety: Incidence of adverse events in 4 different age groups (<60, 60-69, 70-79, >/=80 years) | approximately 4.5 years |
Countries
Germany
Outcome results
None listed